In summary, dismantling the NLRP3-NETs feedback loop represents a promising therapeutic strategy for severe pneumonia, and FZJD provides a clinically derived polypharmacological approach to target these mechanisms. This evidence concerns the gene NLRP3 and susceptibility to pneumonia measurement.